InventisBio
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis 2024-12-03 17:44
InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients 2022-04-11 17:37
InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures 2020-09-28 05:00
Clinical Stage Biotech Company InventisBio Inc. Closes $70 Million USD Series C Financing 2019-03-12 07:00
InventisBio and Betta Pharma to Co-Develop Novel Drug for Non-Small Cell Lung Cancer 2018-12-29 03:33
1